

## **Theravance Biopharma to Present at the Bank of America Merrill Lynch 2015 Health Care Conference**

GEORGE TOWN, GRAND CAYMAN -- (Marketwired) -- 04/30/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today that Rick E Winningham, Chairman and Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015, at 3:00 p.m. PDT. The conference will be held from May 12-14 at the Encore at the Wynn Las Vegas, Las Vegas, NV.

The presentation will be webcast live and can be reached by visiting the Investor Relations section of Theravance Biopharma's website at [www.theravance.com](http://www.theravance.com), under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.

### ***About Theravance Biopharma***

The mission of Theravance Biopharma (NASDAQ: TBPH) is to create value from a unique and diverse set of assets: an approved product; a development pipeline of late-stage assets; and a productive research platform designed for long-term growth.

Our pipeline of internally discovered product candidates includes potential best-in-class opportunities in underserved markets in the acute care setting, representing multiple opportunities for value creation. VIBATIV<sup>®</sup> (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S. and Europe for difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for COPD. Axelopran (TD-1211) is an investigational potential once-daily, oral treatment for opioid-induced constipation (OIC). Our earlier-stage clinical assets represent novel approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease. In addition, we have an economic interest in future payments that may be made by GSK pursuant to its agreements with Theravance, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umecclidinium and vilanterol and (or the "Closed Triple").

With our successful drug discovery and development track record, commercial infrastructure, experienced management team and efficient corporate structure, we believe that we are well positioned to create value for our shareholders and make a difference in the lives of patients. For more information, please visit [www.theravance.com](http://www.theravance.com).

THERAVANCE<sup>®</sup>, the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE<sup>®</sup> and VIBATIV<sup>®</sup> are registered trademarks of the Theravance Biopharma group of companies.

### ***Contact Information:***

Renee Gala  
Chief Financial Officer  
650-808-4045  
[investor.relations@theravance.com](mailto:investor.relations@theravance.com)

Source: Theravance Biopharma

News Provided by Acquire Media